Kerafast, part of Absolute Biotech

Kerafast, part of Absolute Biotech, is dedicated to making unique laboratory-made research tools easily accessible to the global scientific community. Their portfolio includes cell lines, antibodies, small molecules, and dyes, many of which are not available elsewhere. Since its founding in 2011, researchers from more than 170 institutions worldwide have made their innovative reagents available through their online platform, bypassing the traditional Material Transfer Agreement process. Kerafast handles all selling and shipping logistics for the providing laboratory and returns generous royalty payments from every sale, enabling providing labs to save time and resources while generating extra funding for further research. In 2018, Kerafast merged with Absolute Antibody, with a vision to make recombinant antibody technology available to all researchers. In 2022, Kerafast became part of Absolute Biotech, a company uniting multiple life science brands into one organization specializing in antibody reagents and services. The last investment of $100.00K was a Convertible Note investment from FCA Venture Partners and Clayton Associates on 26 February 2016. This strategic integration and investment reflect Kerafast's continued commitment to advancing access to unique research tools and accelerating scientific progress.